A study comparing the pharmacodynamics, efficacy, and safety of linagliptin among Japanese, Asian, and White patients with T2DM showed that a better reduction in HbA1c was achieved in the Asian patients as compared to the Caucasians, without any added safety issue [33]
Am J Gastroenterol 105:27072709 Gluud LL, Knop FK, Vilsboll T (2014) Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
Dr Jasjeet Singh Wasir, director of Endocrinology and Diabetes, Medanta Gurugram, said: Consumers should carefully read product labels and understand that terms such as 'GLP-1 support', 'GLP-1 booster', or 'GLP-1 friendly' do not mean the product contains a GLP-1 medicine or provide the potent clinical benefits like GLP-1. The issue The issue here is not, then, that a law is being broken
This medication can slow gastric emptying, meaning food leaves the stomach more gradually